Point72 Asset Management, L.P. 13D and 13G filings for Arcutis Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 7:50 pm Sale | 2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT | Point72 Asset Management, L.P. | 247,055 0.200% | -4,620,651 (-94.92%) | Filing |
| 2024-01-31 4:54 pm Purchase | 2024-01-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT | Point72 Asset Management, L.P. | 4,867,706 5.200% | 3,680,108 (+309.88%) | Filing |
| 2023-02-14 4:04 pm Sale | 2022-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | Point72 Asset Management, L.P. | 1,187,598 1.900% | -1,470,364 (-55.32%) | Filing |
| 2022-02-14 4:27 pm Purchase | 2021-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | Point72 Asset Management, L.P. | 2,657,962 5.300% | 107,226 (+4.20%) | Filing |
| 2021-12-15 5:14 pm Purchase | 2021-12-14 | 13G | Arcutis Biotherapeutics, Inc. ARQT | Point72 Asset Management, L.P. | 2,550,736 5.100% | 2,550,736 (New Position) | Filing |